A Phase 4 interventional study of Methadone in Opioid Use Disorder, sponsored by Pouya Azar. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Pouya Azar · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.
Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 14th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 19th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Ashish P Thakrar, MD MS · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–99
University of Maryland, Baltimore · Sites in United States
Ages 18–100
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 68 across the 19 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
Pouya Azar is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Pouya Azar has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies testing methadone in Opioid-Related Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT07546396Pouya AzarMethadone Rapid Restart | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing methadone in Opioid-Related Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The usual treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT) with either methadone or buprenorphine. These treatments are well-established, reduce the risk of fatal overdoses, and are considered the standard approach. However, current methadone guidelines were developed when most people were using heroin, which is far less potent than today's unregulated/illicit fentanyl supply. As a result, people who use fentanyl often need higher doses to feel stable. Because methadone must be started at low doses and increased slowly, it can take weeks before someone reaches an effective dose. This process becomes even longer when doses are missed, since treatment often needs to be restarted at a lower level.
The Methadone Rapid Restart is a newer strategy designed to take ongoing fentanyl use into account. Early clinical experience and modelling suggest that many people who use fentanyl have high opioid tolerance and may be able to return to their previous stable methadone dose even after several missed days, without added safety risk. This approach has shown promise in small clinical settings, but it is not yet known whether it provides better outcomes than the standard methadone titration used today. This study will be testing whether this protocol to help rapidly restart people on Methadone is acceptable for patients and use the learning to guide a subsequent larger clinical trial.
Canada continues to see the ongoing effects of the illicit drug overdose in the last decade. Fentanyl and fentanyl analogues account for the majority illicit drug overdose deaths with the highest rate of opioid-related deaths in Canada occurring in British Columbia (BC). Despite this rapid rise in unregulated fentanyl use, treatment strategies for people who use unregulated fentanyl still rely on the opioid use disorder (OUD) treatment guidelines developed from research conducted in people using heroin, a relatively less potent opioid. Currently, methadone and buprenorphine are the recommended medications for opiate use disorder (MOUD).
Methadone at higher doses (at least 60-120mg/day) has shown to have greater effectiveness and treatment retention as compared to lower dosages, based on studies with patient populations using heroin (Bromley et al. 2021). It therefore stands to reason that in the age of unregulated fentanyl, even higher doses of methadone are likely necessary to achieve optimal efficacy and retention rates. Despite this, the highest recommended starting dose of methadone is currently 40mg with a maximum of 15 mg increase every 3 days, for those with a known very high tolerance. As a result, it takes several weeks for people using unregulated fentanyl to reach an effective dose, which is further compounded by missed doses. It is also recommended that if 4 doses of methadone are missed, patients restart at at 50% of their previous dose or at 30-40mg, whichever is higher; and if 5 or more consecutive doses are missed, patients receive a full re-titration, starting from 30-40mg. However, emerging clinical and pharmacokinetic data suggest that, as long as opioid tolerance remains unchanged, methadone can be safely restarted at the same stable dose after missing 4-8 subsequent doses.
The proposed study aims to determine the safety and efficacy of continuing maintenance dose methadone after 4-8 missed doses in people continuing to use unregulated fentanyl to meet their opioid needs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously 'stable' on methadone as per the below definitions:
For participants from VGH study site specifically:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have missed 4-8 doses of methadone, but were on maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period. These participants will be re-initiated on 100% of their most recent methadone dose.
Drug: Methadone
Participants who have missed 4-8 doses of methadone, but were being titrated on methadone prior to discontinuation such that they were on their most recent dosage for less than 5 days but received at least 5 consecutive days of methadone between the prior two dosages (with a maximum of 1 missed dose in that period) be. These participants will be restarted on the lower of their two most recent dosages.
Drug: Methadone
Participants who meet study inclusion criteria and have no exclusion criteria, who have missed 4-8 doses of methadone will, be administered methadone according to the stratification below and will continue the same dose for the 7 day follow up. * Arm 1: Previous maintenance treatment with methadone for opioid use disorder at a stable dose for at least 5 consecutive days prior to discontinuing, with allowance for a maximum of 1 missed dose within that 5-day period. These participants will be re-initiated on 100% of their most recent methadone dose. * Arm 2: Participant was being titrated on methadone prior to discontinuation such that they were on their most recent dosage for less than 5 days but received at least 5 consecutive days of methadone between the prior two dosages (with a maximum of 1 missed dose in that period) be. These participants will be restarted on the lower of their two most recent dosages.
Also known as: Metadol-D, Methadose
Enrollment rate
Number of participants enrolled per month
Time frame: Enrollment
Patient Satisfaction
At the end of the follow up period participants will be asked, "Overall, how satisfied were you with the methadone restart protocol?" The response will be recorded on a 7-point scale: 1=extremely dissatisfied; 2= very dissatisfied; 3= somewhat dissatisfied; 4=neither satisfied nor dissatisfied; 5=somewhat satisfied; 6=very satisfied; 7=extremely satisfied.
Time frame: Assessed retrospectively at the end of 7 day follow up period.
Recruitment
Number of patients approached, eligible, and enrolled
Time frame: Through study completion, anticipated to be 12 months
Level of sedation
Pasero Opioid-Induced Sedation Scale (Score range: 1-4) : Minimal/No sedation (score: 1-2), High sedation (score: 3-4)
Time frame: Baseline, Intervention (1, 2, and 3 hour post-dose) and follow up (Day 1, 3 and 7)
Blood Pressure
Systolic and diastolic blood pressure
Time frame: Baseline, intervention (1,2, and 3 hour post methadone dose), and follow up (Day 1, 3, and 7)
Oxygen saturation
Oxygen saturation
Time frame: Baseline, intervention (1, 2, and, 3 hour post dose) and follow up (Day 1, 3, and 7)
Respiratory rate
Respiration rate
Time frame: Baseline, intervention (1, 2 and 3 hour after post methadone dose), and follow up (Day 1, 3, and 7)
Heart rate
Heart rate
Time frame: Baseline, intervention (1, 2 and 3 hour after post methadone dose), and follow up (Day 1, 3, and 7)
Change in unregulated substance use patterns
The change in the unregulated substance use patterns assessed at baseline and end of the methadone restart protocol
Time frame: Baseline and follow up (Day 1, 3, and 7)
ECG
QTc levels in Electrocardiogram
Time frame: Baseline and follow up (Day 3 and 7)
Adverse events
Incidence of adverse events (AEs) possibly/probably/definitely related to the study drug
Time frame: During intervention and follow up
OAT retention
Retention of methadone and other opioid agonist therapy
Time frame: Follow up
Overdose and hospitalization
Rate of overdose and hospitalization
Time frame: Follow up
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.
Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 10 months is below that.
Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone